AOD9604 (hGH Fragment 176-191): The Monash Research Timeline, Study by Study

AOD9604 is often called "hGH fragment 176-191," but its story is less a single discovery than a 15-year effort by one Monash University laboratory. The question was whether the fat-metabolism activity of human growth hormone (hGH) could be separated from the rest of the hormone. This Vial Post explainer retraces that effort study by study, lays out what each experiment did and did not show, and closes with where U.S. regulators currently place the compound.

The Vial Post discusses AOD9604 only as a subject of laboratory and literature research. Nothing here describes use in people or animals.

Key Facts

• Structure: hGH residues 177-191 with an extra tyrosine on the N-terminus, written Tyr-hGH(177-191). Because hGH residue 176 is phenylalanine, the same 16-residue peptide is often loosely labelled "176-191."
• Origin: the Ng group at Monash University, Australia (Wu & Ng 1993; Ng 2000).
• Main finding in animal studies: effects on fat metabolism without the hGH-receptor binding and glucose effects of intact hGH (Heffernan 2001a).
• Regulatory status: not an FDA-approved drug. FDA has published concerns about compounded AOD-9604 (FDA bulk substances list).

Research Timeline

1993: Locating the domain. Wu and Ng synthesized hGH 177-191 (Leu-Arg-Ile-Val-Gln-Cys-Arg-Val-Ser-Glu-Gly-Ser-Cys-Gly-Phe) and found antilipogenic activity matching the intact hormone in rat fat tissue. Interestingly, they saw no significant lipolytic effect from that early peptide, measured as glycerol release (Wu & Ng 1993). They concluded that the C-terminal region carries the hormone's antilipogenic function.

2000: The first analog, AOD9401. The group made a solid-phase synthetic version of the 177-191 domain. In isolated rat fat tissue it stimulated hormone-sensitive lipase and inhibited acetyl-CoA carboxylase, as intact hGH does. In obese Zucker rats treated for 20 days, average fat-cell diameter fell from about 110 to 80 micrometres, and unlike hGH the peptide did not cause insulin resistance or glucose intolerance (Ng 2000b).

2000: Oral administration. The same lab gave AOD-9401 orally to obese (ob/ob) mice for 30 days. Weight gain was lower than in saline controls from day 16 onward, with no difference in food intake, and treated fat tissue showed lower lipogenic and higher lipolytic activity. The peptide also changed lipolytic and lipogenic activity in isolated human fat tissue in vitro (Heffernan 2000).

2000: AOD9604 proper. The tyrosine-modified analog, AOD9604, was tested orally in obese Zucker rats for 19 days and cut body-weight gain by more than half compared with controls (15.8 vs 35.6 g). The authors reported no adverse effect on insulin sensitivity in euglycemic clamp tests, unlike chronic hGH (Ng 2000a).

2001: Ruling out the growth-hormone receptor. Two 2001 papers tackled mechanism. In obese mice given AOD9604 for 14 days by mini-pump, weight gain fell, fat oxidation and plasma glycerol rose, and blood glucose and insulin secretion were unaffected. In cells engineered to express the hGH receptor, AOD9604 did not compete for receptor binding and did not drive proliferation, both of which hGH does (Heffernan 2001a). The second paper linked the long-term effects to beta-3 adrenergic receptor (beta3-AR) expression. Both hGH and AOD9604 restored low beta3-AR RNA levels in obese mice, and the long-term effects disappeared in beta3-AR knock-out mice. AOD9604 still raised energy expenditure and fat oxidation acutely in knock-out animals, so the authors concluded its lipolytic action is not mediated directly through beta3-AR (Heffernan 2001b).

2014: Safety package. A toxicology and pharmacokinetics summary reported no genotoxicity in Ames, chromosomal aberration and micronucleus assays. Chronic oral dosing was generally well tolerated in rats and cynomolgus monkeys, and oral peptide given to pigs was absorbed and then degraded rapidly (Moré & Kenley 2014).

2015: A new model system. Researchers injected AOD9604, with or without hyaluronic acid, into the knee joints of rabbits with collagenase-induced osteoarthritis. Treated groups had better gross and histological scores than controls, and the combination did best (Kwon & Park 2015). This was a single animal study, not evidence of an effect outside that model.

Reading the Evidence Carefully

Three points recur when the studies are read together:

• Nearly all of the foundational work comes from one group. The 1993 to 2001 papers share the Monash laboratory, so independent replication is limited.
• The early fragment and the final analog are not interchangeable. The unmodified 177-191 peptide showed antilipogenic but not lipolytic activity in 1993 (Wu & Ng 1993), while later analogs were reported to do both (Ng 2000b; Ng 2000a).
• Mechanism is still incomplete. The data rule out hGH-receptor binding and direct beta3-AR action (Heffernan 2001a; Heffernan 2001b), but they do not identify the receptor the peptide does act through.

Regulatory Picture

AOD-9604 was among the peptides nominated for use in U.S. compounding. FDA's list of bulk drug substances that may present significant safety risks records AOD-9604 among nominations that were later withdrawn by their nominators. The agency summarized that compounded AOD-9604 "may pose significant risk for immunogenicity" for certain routes and may involve peptide-impurity and characterization problems. It said it had identified "no, or only limited, safety-related information," and noted serious adverse events that may be associated with the peptide, "though causality is not clear" (FDA bulk substances list).

Questions Readers Ask

Is AOD9604 the same as "HGH fragment 176-191"? In common usage, yes. Strictly, it is Tyr-hGH(177-191): hGH residues 177-191 plus an N-terminal tyrosine.

Does AOD9604 act like growth hormone? In the reported studies, no. It did not bind the hGH receptor or stimulate receptor-driven cell proliferation, and it did not reproduce hGH's effects on glucose and insulin (Heffernan 2001a; Ng 2000a).

Is it approved for any use? No. It is not an FDA-approved drug, and FDA has published safety concerns about compounded AOD-9604 (FDA bulk substances list).

Handling in the Lab

AOD9604 is generally supplied as a lyophilized powder. Standard peptide practice applies: store it cold (commonly -20 degrees C), keep it dry and away from light, reconstitute only when needed, and avoid repeated freeze-thaw cycles. Verify identity and purity against each batch's Certificate of Analysis.

For research and educational use only. This article is not medical advice and does not describe dosing or human use.